Founders
Dr. Guang Yang
Chairman and Chief Scientific Officer (CSO)
Dr. Yang had been working in several multinational pharmaceutical companies such as Novartis, Roche, and Johnson & Johnson. Prior to founding Aubrak Therapeutics, he was the R&D Director of Johnson & Johnson at the China R&D Center. ?He has more than 20 years of leadership experience in drug discovery and development. Throughout his tenure in these companies, he had successfully led and participated in quite a few new drug discovery projects.
Dr. Yang obtained his Ph.D. degree from the Hebrew University of Jerusalem, Israel, and conducted his postdoctoral research at the Howard Hughes Medical Institute, University of Southern California, USA.
Dr. Jeff Zhang?
Chief Executive Officer (CEO)
Dr. Zhang has nearly 30 years of experience in innovative drug development and management. Prior to founding Aubrak Therapeutics, he served as the director of Novartis Institutes of Biomedical Research and the CSO of Youngene Therapeutics. He has previously worked in many top multinational pharmaceutical companies such as Pfizer and GlaxoSmithKline. He has rich experience in novel drug research and development, has published more than 50 research papers in peer-reviewed journals, and holds numerous international patents.
Dr. Zhang has led and participated in dozens of innovative drug projects ranging from early-stage new drug discovery to translational medicine and clinical stage, of which 8 drugs are now on the market (Celebrex, Bextra, Dynastat, Inspra, Tykerb, Navelbine, IncruseEllipta, Scemblix).
Dr. Zhang obtained his Ph.D.degree in organic chemistry from Shanghai Institute of Materia Medica, Chinese Academy of Sciences and a bachelor's degree in chemistry from Hangzhou University (now Zhejiang University). He conducted his postdoctoral research in clinical pharmacology at Vanderbilt University, USA.
Dr. ZHENGMING DU
Chief Technology Officer(CTO)
Dr. Zhengming Du possesses over 30 years of the pharmaceutical industry and academic experience including early drug discovery, late drug development, registration, and commercialization. He also has extensive experience in management and has been leading global teams to succeed in multiple IND and NDA approvals. Before being co-founder and CTO of Aubrak Therapeutics, Dr. Du used to work as a senior vice president at BeiGene, director at Roche (China), deputy general manager of Huahai Pharmaceuticals, and leading chemist in Novartis USA.
Dr. Du holds a Ph.D. from Clark University in the United States, and a bachelor's degree in chemistry from Nanjing University. He has published more than 30 peer-reviewed scientific papers and authorized more than 20 international and domestic patents. He has won many awards including the Novartis Pharmaceuticals Global Resource Efficiency Award, Roche Innovation Project Outstanding Contribution Award, Chinese Chemical Society Outstanding Young Chemist Award, Jiangsu Science and Technology Progress Award, Leader of Major Scientific and Technological Innovation Projects in Jiangsu Province, Leader of Jiangsu Double Entrepreneurship Team and National Talent Experts.
Pre-A輪重要投資機構
南京復星通?；鹗菄H化醫(yī)藥健康產業(yè)集團復星醫(yī)藥（600196.SH,02196.HK）旗下的創(chuàng)業(yè)投資基金，基金在南京江北科投集團的支持下于2021年7月設立，規(guī)模5億元人民幣，專注投資于中早期生物醫(yī)藥企業(yè)，由通德資本擔任基金管理人。通德資本是一家專注于投資生物醫(yī)藥的VC機構，主要投資創(chuàng)新藥和創(chuàng)新生物技術等領域，以早期和成長期項目為主。團隊擁有深厚的產業(yè)背景、豐富的產業(yè)和金融資源、以及孵化和助力被投公司成為行業(yè)領導者的成功經驗。
南京其瑞佑康基金成立于2018年，是由南京江北科投集團出資設立、規(guī)模7億人民幣的創(chuàng)業(yè)投資基金，由恩然創(chuàng)投擔任基金管理人，是一只專注于生物技術、醫(yī)療醫(yī)藥的科技創(chuàng)新股權投資基金?；鹪O立以來深耕江北新區(qū)，已累計投資醫(yī)療科技企業(yè)10多家，包括藥捷安康、維立志博、征祥醫(yī)藥等。恩然創(chuàng)投成立于2015年，專注于生命科學、健康醫(yī)療、創(chuàng)新，秉承主動投資理念，在全球生物醫(yī)藥和醫(yī)療健康產業(yè)鏈戰(zhàn)略性地對產業(yè)中的革命性新技術、新產品進行投資布局。
銳合資本由資深的產業(yè)和金融界人士于2010年創(chuàng)設，專注信息技術、醫(yī)藥健康和文化創(chuàng)意領域的股權投資，目前管理資金近30億元，近年來A股上市案例包括泛微網絡、美諾華、保隆科技、綠色動力、泰坦科技等。醫(yī)藥健康方面，依托來自醫(yī)藥界的專業(yè)團隊，銳合資本已領導投資了美諾華、阿諾醫(yī)藥、華先醫(yī)藥、智核生物、美克醫(yī)學等優(yōu)秀企業(yè)。
成都苑東生物制藥股份有限公司是一家以研發(fā)創(chuàng)新驅動的，集化學原料藥、高端化學藥及生物藥研發(fā)、生產、銷售于一體的高新技術企業(yè)，公司成立于2009年，并于2020年9月在上海證券交易所科創(chuàng)板掛牌上市（股票簡稱：苑東生物，股票代碼：688513）。
